Search the Newsreel

Hennion & Walsh Asset Management Inc. Acquires 347,872 Shares of Verastem, Inc. $VSTM

Hennion & Walsh Asset Management Inc. significantly increased its stake in Verastem, Inc. (NASDAQ:VSTM) by 157.2%, acquiring an additional 347,872 shares, bringing their total ownership to 569,195 shares valued at $2.17 million. This move is part of broader institutional interest, with collective institutional ownership …

VSTM Maintains by Mizuho -- Price Target Lowered to $13.00

Mizuho maintained an "Outperform" rating for Verastem (VSTM) but lowered its price target from $14.00 to $13.00, reflecting market sentiment and challenges despite the company's focus on novel anticancer agents. Verastem's GF Score™ of 14/100 highlights significant financial and profitability struggles, with insider activity …

Mizuho lowers Verastem stock price target on valuation to $13

Mizuho has lowered its price target for Verastem Inc. (NASDAQ:VSTM) to $13 from $14, while maintaining an Outperform rating, following strong Q2 2026 results that surpassed analyst expectations. The company reported significant revenue growth, a high gross profit margin, and secured new financing, extending …

Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating

Mizuho Securities has lowered its price target for Verastem (VSTM) to $13 from $14, while maintaining an Outperform rating on the stock. According to analysts, Verastem currently holds an average "buy" rating with a mean price target of $14.75. Access to the full MT …

State Street Corporation (VSTM) discloses 5.8% beneficial ownership in INC common stock

State Street Corporation has disclosed a 5.8% beneficial ownership stake in Verastem Inc. (VSTM) common stock through a SCHEDULE 13G filing. This represents 5,133,859 shares held with shared voting and dispositive power through its investment management subsidiaries. The filing indicates a neutral sentiment and …

A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $12 to $18

This article provides a quick overview of recent analyst ratings for Verastem (VSTM.US), highlighting that analysts have set price targets ranging from $12 to $18. The information suggests a positive outlook for the company's stock from the perspective of financial analysts.

Verastem (VSTM) Stock Rallies On Revenue Surge And Pipeline Pressure

Verastem, Inc. Stock 12‑Month Price Target Cut to $14.88, Implies 152% Upside

Verastem, Inc.'s average price target has been lowered from $15 to $14.88 by 8 analysts, with individual forecasts ranging from $9 to $18 per share. This updated target suggests a potential upside of approximately 152% from its Aug. 6 closing price. The consensus rating …

Verastem Inc (VSTM) Stock News Today

This article from TradingKey provides current stock information for Verastem Inc (VSTM), noting a 14.04% increase in its stock price to $6.740. It offers an overview of the company's market cap and indicates that more news, earnings, analyst ratings, and key developments will be …

Verastem (NASDAQ:VSTM) Posts Earnings Results, Beats Estimates By $0.08 EPS

Verastem Amends Oberland Financing, Adding Up to $75 Million Revenue-Share Notes Maturing 2033

Verastem has amended its financing agreement with Oberland Capital-managed funds and RGCM SA to introduce up to $75 million in new revenue-backed senior secured notes, maturing in 2033. The new notes include an initial $50 million tranche available by August 28, 2026, and an …

Verastem (NASDAQ:VSTM) Shares Gap Up Following Better-Than-Expected Earnings

Verastem, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:VSTM) 2026-08-07

Verastem Inc (VSTM) (Q2 2026) Earnings Call Highlights: Strong Revenue Rebound and Strategic ...

Verastem Inc (VSTM) reported strong Q2 2026 net product revenues of $25.1 million, reflecting a significant rebound due to improved commercial execution for its LGSOC franchise. The company also secured a non-dilutive royalty financing agreement of up to $75 million, strengthening its balance sheet …

Verastem, Inc. 2026: Revenue $40.08M, EPS ($0.35) — 10-Q Summary

Verastem, Inc. reported its 2026 quarterly results, showing a significant increase in revenue to $40.08M from $2.14M in the prior year, primarily due to the commercial launch of AVMAPKI FAKZYNJA CO-PACK. The company also narrowed its net loss to ($34.67M) and improved diluted loss …

Verastem earnings beat by $0.12, revenue topped estimates

Verastem (NASDAQ: VSTM) reported strong second-quarter results, beating analyst EPS estimates by $0.12 with earnings of $-0.310 and significantly exceeding revenue forecasts at $40.07M against an estimated $23.09M. The company's stock has seen a 20.860% increase in the last three months and a 5.160% …

Earnings call transcript: Verastem beats Q2 2026 estimates, shares jump after hours

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

Verastem (VSTM) reported a Q2 loss of $0.35 per share, surpassing the Zacks Consensus Estimate of a $0.46 loss and exceeding prior year's loss of $0.39. The company's revenues for the quarter reached $40.08 million, significantly beating the Zacks Consensus Estimate by 73.12% and …

Verastem (Nasdaq: VSTM) lifts Q2 2026 revenue to $40M, discloses going‑concern risk

BlackRock, Inc. Trims Verastem Inc (VSTM) Stake in Recent 13DG Filing

BlackRock, Inc. has reduced its stake in Verastem Inc (VSTM) by 7,913 shares, a 0.13% decrease, as disclosed in a recent 13G filing. The biopharmaceutical company, specializing in anticancer agents, faces significant financial and operational challenges, reflected in its low GF-Score and weak profitability …

Verastem, Inc. (VSTM) CEO sells 1,302 shares to cover RSU taxes

Verastem, Inc. CEO Dan Paterson sold 1,302 shares of common stock on August 3, 2026, at a price of $5.81 per share. This transaction was executed to fulfill statutory tax withholding requirements associated with the vesting of restricted stock units (RSUs) and was conducted …

VSTM|Verastem Inc|Price:5.695|Chg%:-0.105

Verastem Inc (VSTM) shows healthy fundamentals and high growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. Institutional ownership is notably high, and analysts currently rate the stock as a "Buy" with a target price indicating significant upside. …

A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $14 to $18

This article provides an overview of current analyst ratings for Verastem (VSTM.US), highlighting a consensus price forecast ranging from $14 to $18. It serves as a quick snapshot of market sentiment and expectations for the company's stock performance.

Vanguard Capital Management (VSTM) discloses 4.42M Verastem shares in 13G filing

Vanguard Capital Management LLC has filed a Schedule 13G, reporting a beneficial ownership of 4,423,544 shares of Verastem Inc (VSTM) common stock as of June 30, 2026. This represents a 5.03% stake in the company. Vanguard holds sole voting power over 572,036 shares and …

Verastem, Inc. Revenue Breakdown – NASDAQ:VSTM

Verastem, Inc. (NASDAQ: VSTM) reported its revenue breakdown, with the Drugs segment being the top performer. The company generated $30.91 million USD last year, primarily from the United States, an increase from $10.00 million USD in the previous year.

Verastem Inc (VSTM) Valuation: PE, PB & Fair Value Analysis

Verastem Inc (VSTM) currently holds a valuation score of 6.10, placing it in the lower quartile of the Biotechnology & Medical Research industry. Its P/E ratio is -2.51, representing a significant drop from its recent high and a moderate increase from its recent low. …

Verastem (VSTM) to Post Quarterly Earnings on Thursday

VSTM|Verastem Inc|Price:6.013|Chg%:-0.217

This article provides a comprehensive stock analysis of Verastem Inc (VSTM) by TradingKey, highlighting its healthy fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. The company's stock is rated "Buy" by multiple analysts with a target price …

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer

Verastem Oncology has dosed the first patient in its TARGET-D 203 Phase 2 clinical trial, evaluating the investigational oral KRAS G12D inhibitor VS-7375 for metastatic colorectal cancer (mCRC). This marks the initiation of treatment across all three of Verastem's registration-directed Phase 2 trials for …

Verastem Inc (VSTM) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Verastem Inc (VSTM), focusing on its support and resistance levels, various technical indicators, and moving averages. As of July 28, 2026, VSTM has a price momentum score of 6.17 and is trading between a resistance level of …

Verastem’s VS-7375 trials now span pancreatic, colorectal and lung cancers

Verastem Oncology has dosed the first patient in its TARGET-D 203 Phase 2 trial for VS-7375, an oral KRAS G12D inhibitor, targeting metastatic colorectal cancer. This marks the initiation of treatment across all three of its TARGET-D registration-directed Phase 2 trials for VS-7375, which …

Verastem Inc (VSTM) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Verastem Inc (VSTM), identifying its major institutional and individual holders. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in holdings for key investors. The report also lists …

Verastem Inc (VSTM) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Verastem Inc (VSTM), giving it a score of 8.71, ranking it 32 out of 386 in the Biotechnology & Medical Research industry. The company is noted for its stable financial status and high operating efficiency, although …